Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Zoster vaccine recombinant
- Development stage
- Approved
- Lead developer
- GSK
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Zoster vaccine recombinant is a non-live, adjuvanted recombinant protein vaccine used to prevent herpes zoster (shingles) and its complications in adults. The active component is the varicella zoster virus surface glycoprotein E (gE), produced using recombinant DNA technology. It is formulated with the AS01B adjuvant to enhance immune response. The primary mechanism of action involves boosting active immunity against varicella-zoster virus by stimulating both humoral and cell-mediated immune responses specific to VZV gE antigen. Zoster vaccine recombinant is administered as a two-dose intramuscular series, typically 2–6 months apart. It was developed for use in adults aged 50 years and older, as well as immunocompromised individuals at increased risk of shingles[1][2][4][5][6]. The developer and manufacturer is GSK.
- Brand names
- Shingrix
- Other names
- recombinant zoster vaccineRZVshingles vaccine (recombinant)herpes zoster vaccine (recombinant)
02
Targets
gE (VZV glycoprotein E)
Beyond the preview
Go deeper on Zoster vaccine recombinant.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Zoster vaccine recombinant.